Karen Akinsanya

Insider Reports History

Entity
Individual
Location
Schrodinger, Inc., 120 West 45 Th Street, 17 Th Floor, New York, NY
Signature
/s/ Mathew B. Murphy, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Karen Akinsanya:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Schrodinger, Inc. President of R&D, Therapeutics Stock Option (right to buy) 120K Mar 4, 2024 Direct
Nautilus Biotechnology, Inc. Director Stock Option (Right to Buy) 45K Jun 14, 2024 Direct

Insider Reports Filed by Karen Akinsanya

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NAUT Nautilus Biotechnology, Inc. Jun 14, 2024 1 $0 4 Jun 17, 2024 Director
SDGR Schrodinger, Inc. Mar 4, 2024 1 $0 4 Mar 5, 2024 President of R&D, Therapeutics
NAUT Nautilus Biotechnology, Inc. Jun 15, 2023 1 $0 4 Jun 16, 2023 Director
SDGR Schrodinger, Inc. Feb 9, 2023 1 $0 4 Feb 10, 2023 President of R&D, Therapeutics
NAUT Nautilus Biotechnology, Inc. Jun 15, 2022 1 $0 4 Jun 16, 2022 Director
NAUT Nautilus Biotechnology, Inc. Mar 30, 2022 1 $0 4 Mar 31, 2022 Director
NAUT Nautilus Biotechnology, Inc. Mar 30, 2022 0 $0 3 Mar 31, 2022 Director
SDGR Schrodinger, Inc. Feb 9, 2022 1 $0 4 Feb 9, 2022 EVP, Chief Biomedical Scientist, Head of Discovery R&D
SDGR Schrodinger, Inc. Oct 15, 2021 3 -$71.6K 4 Oct 19, 2021 EVP, Chief Biomedical Scientist, Head of Discovery R&D
SDGR Schrodinger, Inc. Sep 15, 2021 3 -$79.2K 4 Sep 16, 2021 EVP, Chief Biomedical Scientist, Head of Discovery R&D
SDGR Schrodinger, Inc. Aug 16, 2021 8 -$1.78M 4 Aug 17, 2021 EVP, Chief Biomedical Scientist, Head of Discovery R&D
SDGR Schrodinger, Inc. Jun 7, 2021 7 -$1.19M 4 Jun 9, 2021 EVP, Chief Biomedical Scientist, Head of Discovery R&D